Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · Real-Time Price · USD
5.91
+0.01 (0.17%)
At close: Oct 29, 2024, 4:00 PM
5.96
+0.05 (0.85%)
After-hours: Oct 29, 2024, 6:22 PM EDT
Revance Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 251.18 | 234.04 | 132.57 | 77.8 | 15.33 | 0.41 | Upgrade
|
| Revenue Growth (YoY) | 40.23% | 76.55% | 70.40% | 407.65% | 3610.65% | -88.92% | Upgrade
|
| Cost of Revenue | 154.62 | 152.16 | 152.95 | 139.67 | 130.56 | 102.86 | Upgrade
|
| Gross Profit | 96.56 | 81.88 | -20.39 | -61.87 | -115.24 | -102.45 | Upgrade
|
| Selling, General & Admin | 294.48 | 296.47 | 223.93 | 198.82 | 147.95 | 62.01 | Upgrade
|
| Research & Development | -4.86 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 295.57 | 302.6 | 251.78 | 212.81 | 154.02 | 62.01 | Upgrade
|
| Operating Income | -199.01 | -220.73 | -272.17 | -274.68 | -269.26 | -164.46 | Upgrade
|
| Interest Expense | -21.43 | -19.36 | -16.47 | -6.27 | -15.15 | - | Upgrade
|
| Interest & Investment Income | 13.34 | 13.29 | 4.89 | 0.34 | 4.32 | 5.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.9 | -0.84 | -2.18 | -0.7 | -0.72 | -0.5 | Upgrade
|
| EBT Excluding Unusual Items | -207.99 | -227.63 | -285.93 | -281.31 | -280.81 | -159.43 | Upgrade
|
| Merger & Restructuring Charges | -2.87 | -2.87 | - | - | -3.9 | - | Upgrade
|
| Impairment of Goodwill | -77.18 | -77.18 | -69.79 | - | - | - | Upgrade
|
| Asset Writedown | -16.01 | -16.01 | - | - | - | - | Upgrade
|
| Pretax Income | -304.04 | -323.69 | -355.72 | -281.31 | -284.71 | -159.43 | Upgrade
|
| Income Tax Expense | 0.3 | 0.3 | 0.7 | - | -2.62 | - | Upgrade
|
| Net Income | -287.5 | -323.99 | -356.42 | -281.31 | -282.09 | -159.43 | Upgrade
|
| Net Income to Common | -287.5 | -323.99 | -356.42 | -281.31 | -282.09 | -159.43 | Upgrade
|
| Shares Outstanding (Basic) | 92 | 85 | 73 | 68 | 58 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 85 | 73 | 68 | 58 | 43 | Upgrade
|
| Shares Change (YoY) | 16.41% | 16.35% | 7.71% | 16.37% | 33.47% | 20.15% | Upgrade
|
| EPS (Basic) | -3.11 | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 | Upgrade
|
| EPS (Diluted) | -3.11 | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 | Upgrade
|
| Free Cash Flow | -209.22 | -223.46 | -196.76 | -231.91 | -182.6 | -109.39 | Upgrade
|
| Free Cash Flow Per Share | -2.27 | -2.64 | -2.71 | -3.44 | -3.15 | -2.52 | Upgrade
|
| Gross Margin | 38.44% | 34.98% | -15.38% | -79.52% | - | - | Upgrade
|
| Operating Margin | -79.23% | -94.31% | -205.31% | -353.06% | -1757.01% | -39820.58% | Upgrade
|
| Profit Margin | -114.46% | -138.43% | -268.87% | -361.59% | -1840.71% | -38602.66% | Upgrade
|
| Free Cash Flow Margin | -83.30% | -95.48% | -148.42% | -298.10% | -1191.52% | -26486.92% | Upgrade
|
| EBITDA | -192.06 | -207.03 | -233.02 | -254.82 | -259.01 | -161.55 | Upgrade
|
| EBITDA Margin | -76.46% | -88.46% | -175.78% | - | - | - | Upgrade
|
| D&A For EBITDA | 6.95 | 13.69 | 39.15 | 19.85 | 10.25 | 2.91 | Upgrade
|
| EBIT | -199.01 | -220.73 | -272.17 | -274.68 | -269.26 | -164.46 | Upgrade
|
| EBIT Margin | -79.23% | -94.31% | -205.31% | - | - | - | Upgrade
|
| Revenue as Reported | 251.18 | 234.04 | 132.57 | 77.8 | 15.33 | 0.41 | Upgrade
|
| Advertising Expenses | - | 8.4 | 5.1 | 6.2 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.